Lung Cancer
Volume 70, Issue 1 , Pages 110-115 , October 2010

Population-based patterns and cost of management of metastatic non-small cell lung cancer after completion of chemotherapy until death

  • Sri Navaratnam

      Affiliations

    • Department of Internal Medicine, University of Manitoba, Faculty of Medicine, 675 McDermot Avenue, Winnipeg, R3E 0V9 Canada
    • Corresponding Author InformationCorresponding author.
    • ,
  • Erich V. Kliewer

      Affiliations

    • Epidemiology and Cancer Registry, CancerCare Manitoba, Winnipeg, Canada
    • Department of Community Health Sciences, University of Manitoba, Winnipeg, Canada
    • ,
  • Jim Butler

      Affiliations

    • Australian Centre for Economic Research on Health, College of Medicine and Health Sciences, Australian National University, Canberra, Australia
    • ,
  • Alain A. Demers

      Affiliations

    • Epidemiology and Cancer Registry, CancerCare Manitoba, Winnipeg, Canada
    • Department of Community Health Sciences, University of Manitoba, Winnipeg, Canada
    • ,
  • Grace Musto

      Affiliations

    • Epidemiology and Cancer Registry, CancerCare Manitoba, Winnipeg, Canada
    • ,
  • Ketan Badiani

      Affiliations

    • Manitoba Institute of Cell Biology, CancerCare Manitoba, Winnipeg, Canada

Received 5 October 2009 ,Revised 11 December 2009 ,Accepted 17 January 2010.

References 

  1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2:533–543
  2. Sher T, Dy WK, Adjei AA. Small cell lung cancer. Mayo Clin Proc. 2008;83:355–367
  3. Travis WD, Travis LB, Devera SS. Lung cancer. Cancer. 1995;75:191–202
  4. Franeschi S, Bidoli E. The epidemiology of lung cancer. Ann Oncol. 1999;10:S3–S6
  5. Stinchcombe TE, Lee CB, Socinski MA. Current approaches to advanced stage non-small cell lung cancer: first line therapy in patients with good functional status. Clin Lung Cancer. 2006;4(7 Suppl.):S111–S117
  6. Soquet PJ, Chauvin F, Boissel JP, Cellerino R, Cormier Y, Ganz PA, et al. Polychemotherapy in advanced non-small cell lung cancer, a meta-analysis. Lancet. 1993;342:19–21
  7. Stinchcombe TE, Socinski MA. Considerations for second-line therapy of non-small cell lung cancer. The Oncologist. 2008;13(Suppl. 1):28–36
  8. Felip E, Rosell R. Pemetrexed as second-line therapy for advanced non-small cell lung cancer (NSCLC). Ther Clin Risk Manage. 2008;4:579–585
  9. Shepherd FA, Pereira JR, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med. 2005;353:123–132
  10. Carlson JJ, Veenstra DL, Ramsey SD. Pharmacoeconomic evaluations in the treatment of non-small cell lung cancer. Drugs. 2008;68:1105–1113
  11. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer. A meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ. 1995;311:899–909
  12. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O’Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18:2095–2103
  13. Ramsey SD, Martins RG, Blough DK, Tock LS, Lubeck D, Reyes CM. Second-line and third-line chemotherapy for lung cancer: Use and Cost. Am J Manage Care. 2008;14:297–306
  14. Schiller JH, Harrington D, Belani C, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92–98
  15. Ng R, Hasan B, Mittmann N, Florescu M, Shepherd FA, Ding K, et al. Economic analysis of NCIC CTG JBR.10: A randomized trial of adjuvant vinorelbine plus cisplatin compared with observation in early stage non-small-cell lung cancer—A report of the working group on economic analysis, and the lung disease site group, National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:2256–2261
  16. Leighl N, Shepherd FA, Kwong R, Burkes RL, Feld R, Goodwin PJ. Economic analysis of the TAX 317 trial: Docetaxel versus best supportive care as second-line therapy of advanced non-small-cell lung cancer. J Clin Oncol. 2002;20:1344–1352
  17. Evans WK, Will BP, Berthelot JM, Wolfson MC. The cost of managing lung cancer in Canada. Oncology. 1995;11(9 Suppl.):147–153
  18. Molinier L, Combescure C, Chouaïd C, Daurès JP, Housset B, Fabre D, et al. Cost of lung cancer—a methodological review. Pharmacoeconomics. 2006;24:651–659
  19. Pompen M, Gok M, Novak A, van Wuijtswinkel R, Biesma B, Schramel F, et al. Direct costs associated with the disease management of patients with unresectable advanced non-small cell lung cancer in The Netherlands. Lung Cancer. 2009;64:110–116
  20. Braud A-C, Levy-Piedbois C, Piedbois P, Piedbois Y, Livartovski A, Le Vu B, et al. Direct treatment costs for patients with lung cancer from first recurrence to death in France. Pharmacoeconomics. 2003;21:671–679
  21. Dede KJ, Szucs TD, Bodes S, Joerger M, Lowy A, Russi EW, et al. Management and costs of treating lung cancer patients in a University Hospital. Pharmacoeconomics. 2004;22:435–444

PII: S0169-5002(10)00026-7

doi: 10.1016/j.lungcan.2010.01.012

Lung Cancer
Volume 70, Issue 1 , Pages 110-115 , October 2010

Article Tools

* Image Usage & Resolution